Associations - STK11 (Serine/threonine kinase 11)

STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	nivolumab Resistant: B - Late Trials nivolumab Resistant : B	nivolumab Resistant: B - Late Trials nivolumab Resistant : B
NFE2L2 mutation + STK11 mutation	Non Small Cell Lung Cancer	NFE2L2 mutation + STK11 mutation	Non Small Cell Lung Cancer	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	durvalumab Resistant: B - Late Trials durvalumab Resistant : B	durvalumab Resistant: B - Late Trials durvalumab Resistant : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	Sensitive: B - Late Trials Sensitive : B	Sensitive: B - Late Trials Sensitive : B
STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	durvalumab + tremelimumab-actl Sensitive: B - Late Trials durvalumab + tremelimumab-actl Sensitive : B	durvalumab + tremelimumab-actl Sensitive: B - Late Trials durvalumab + tremelimumab-actl Sensitive : B
5-genomic mutation signature	Non Small Cell Lung Cancer	5-genomic mutation signature	Non Small Cell Lung Cancer	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B	BGB324 Sensitive: B - Late Trials BGB324 Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	pembrolizumab + BGB324 Sensitive: B - Late Trials pembrolizumab + BGB324 Sensitive : B	pembrolizumab + BGB324 Sensitive: B - Late Trials pembrolizumab + BGB324 Sensitive : B
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	bevacizumab + atezolizumab Sensitive: B - Late Trials bevacizumab + atezolizumab Sensitive : B	bevacizumab + atezolizumab Sensitive: B - Late Trials bevacizumab + atezolizumab Sensitive : B
KRAS mutation + STK11 mutation + KEAP1 mutation	Non Small Cell Lung Cancer	KRAS mutation + STK11 mutation + KEAP1 mutation	Non Small Cell Lung Cancer	bevacizumab + atezolizumab Sensitive: B - Late Trials bevacizumab + atezolizumab Sensitive : B	bevacizumab + atezolizumab Sensitive: B - Late Trials bevacizumab + atezolizumab Sensitive : B
KRAS G12C + STK11 mutation	Non Small Cell Lung Cancer	KRAS G12C + STK11 mutation	Non Small Cell Lung Cancer	sotorasib Sensitive: B - Late Trials sotorasib Sensitive : B	sotorasib Sensitive: B - Late Trials sotorasib Sensitive : B

STK11 (Serine/threonine kinase 11)

Associations(99)

Associations
(99)